The coronavirus disease 2019 (COVID-19) Epidemiology Forecaster is a fully customizable SEIR(susceptible, exposed, infectious, recovered) model that allows users to develop scenario-based global…
The number of total prevalent cases of MCI across the Asia-Pacific countries under study will increase by 55%, from 11 million in 2020 to 17 million in 2030. Among the countries considered…
Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…
Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…
The number of total prevalent cases of MCI across the countries under study will increase by 39%, from 2.8 million in to 3.9 million in 10 years. Among the countries considered in this…
The number of total prevalent cases of MCI across the countries under study will increase by 43%, from 58 million in 2020 to 83 million in 2030. Among the countries considered in this…
DRG Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings…
The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primarily effective in treating positive symptoms. However, in late 2019, the U.S…
More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has…
The asthma market in the EU5 is highly competitive. Many approved agents are available, including maintenance therapies—LABA/ICS FDCs (e.g., GSK’s Seretide and Relvar, AstraZeneca’s Symbicort…